Stocks to Watch recap highlights Intel, Samsung, PepsiCo, TSMC
A Wall Street Journal recap cited sector moves tied to chip and consumer updates, including Samsung profit guidance, TSMC September sales, PepsiCo outlook changes and a Pacira deal.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
11 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Dow Jones roundup highlights Microsoft, PepsiCo, Viatris
Dow Jones’ 5 p.m. ET roundup highlights a series of company updates, including Microsoft’s new Xbox unit, PepsiCo’s outlook cut, Viatris’ planned Pacira BioSciences acquisition and Samsung’s profit outlook.
Viatris to acquire Pacira Biosciences for $1.65 billion
Viatris announced a plan to buy Pacira Biosciences for $1.65 billion, driving Pacira shares up while Viatris shares fell.
Dow Jones roundup highlights multiple corporate developments
Dow Jones Newswires listed a series of corporate and regulatory headlines, including Microsoft, PepsiCo, Devon Energy, Viatris and Samsung. The package also included legal, production and deal updates across several companies.
Viatris to buy Pacira BioSciences for $1.65 billion
Viatris said it will acquire Pacira BioSciences for $1.65 billion in cash, or $36.50 a share, a roughly 45% premium to Pacira's Wednesday close. The deal is expected to close by year-end and was followed by a 44% jump in Pacira shares and a 2.2% decline in Viatris.
PepsiCo cuts full-year outlook on North America weakness
PepsiCo cut its full-year earnings outlook as inflation, higher advertising costs and continued weakness in North America weighed on results. The company said it is working to reduce expenses and revive sales.
Viatris Bets Big on Non-Opioid Painkillers With Pacira Buyout
Viatris Inc. (NASDAQ: VTRS ) announced Thursday that it agreed to acquire Pacira BioSciences Inc. (NASDAQ: PCRX ) for $1.65 billion, strengthening its position in non-opioid pain management. Under the agreement, Viatris will pay $36.50 per share in cash for all outstanding Pacira shares. Viatris reported $886.5 million
Viatris to buy Pacira for $1.65 billion in cash
Viatris said it will acquire Pacira BioSciences for $1.65 billion, or $36.50 a share, in cash. The company expects the deal to close by year-end and to have a minimal impact on gross leverage.
PepsiCo trims outlook on North American weakness
PepsiCo cut its full-year earnings outlook, citing inflation, higher advertising costs and continued weakness in North America. The company said it is working to reduce expenses and revive sales.
PepsiCo trims outlook as North American unit underperforms
PepsiCo said its North American unit underperformed and trimmed its outlook. The company reported fiscal third-quarter profit of $3.05 billion, or $2.23 a share, versus $2.6 billion, or $1.90 a share, a year earlier.
Viatris agrees to buy Pacira for $1.65 billion
Viatris will pay $36.50 per share in cash for Pacira BioSciences, a roughly 45% premium to Pacira’s prior close, in a deal set to close by year-end.